RNS Number : 6891S
ReNeuron Group plc
08 November 2023


ReNeuron Group plc

("ReNeuron" or "the Group")


ReNeuron presents in vivo data at Cell 2023


In vivo data highlights the specific tissue and cellular targeting capabilities

of ReNeuron's stem cell derived exosome drug delivery platform, CustomEXTM


ReNeuron Group plc (AIM: RENE), a UK based leader in stem cell derived exosome technologies, announces that Dr Samantha Thomas will be presenting in vivo data exemplifying the cellular and tissue targeting capabilities and highlighting the significant advantages of ReNeuron's CustomEX™ drug delivery platform, at Cell 2023 in London.


Key highlights from the presentation entitled Targeted Delivery of Therapeutic Payloads Using Stem Cell derived Exosome include:


·    Confirmation in vitro and in vivo that exosome targeting is dependent on cell source and selection of a specific exosome population results in the improved delivery of therapeutic payloads when compared to a conventional HEK293 exosome approach.

·    A specific CustomEX™ exosome targets the lymph nodes (immune system) proportionately more than other exosome types. 

·    A specific CustomEX™ exosome selectively targets the tubules within the kidney.

·    A specific CustomEX™ exosome targets the lung following systemic administration. 

·    Confirmation that therapeutic payloads can be successfully delivered in vivo using the CustomEX™ platform following systemic administration.

·    No evidence of immune response or toxicity with any of the exosome candidates, opening up the possible use of CustomEX™ for repeat administration unlike viral vectors.


These data highlight the significant improvement in targeting and delivery of payloads that can be achieved through the careful selection of specific exosomes from different cell sources. ReNeuron's CustomEXTM platform, is a compelling platform that offers this ability to select the exosome cell type for a partner's need and the payload / target cell of their choice, while offering a scalable and repeatable manufacturing process due to its patented conditional immortalisation technology. This technology was enabled through the Group's earlier work in producing GMP stem cells approved by the FDA and MHRA for the clinic from which the Group's exosomes are now produced.


The presentation from the conference will also be available on the ReNeuron website after the event:


CustomEXTM is a register trademark of ReNeuron Limited.





Iain Ross, Executive Chairman

Via Walbrook PR

John Hawkins, Chief Financial Officer

Allenby Capital Limited (Nominated Adviser and Broker)

+44 (0)20 3328 5656

James Reeve / George Payne /

Dan Dearden-Williams (Corporate Finance)

Stefano Aquilino (Sales & Corporate Broking)

Walbrook PR (Media & Investor Relations)

+44 (0)20 7933 8780 or

Paul McManus / Alice Woodings

+44 (0)7980 541 893 / +44 (0)7407 804 654


About ReNeuron

ReNeuron has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customisable cellular targeting capabilities for the delivery of complex drug modalities.


Through the generation of several unique and scalable exosome producer cell lines, our CustomEX™ platform can be optimised for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. ReNeuron offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. Through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, the Group can make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.


ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit


This announcement contains forward-looking statements with respect to the financial condition, results of operations and business achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto. These statements may generally, but not always, be identified by the use of words such as "should", "expects", "estimates", "believes" or similar expressions. This announcement also contains forward-looking statements attributed to certain third parties relating to their estimates regarding the growth of markets and demand for products. By their nature, forward-looking statements involve risk and uncertainty because they reflect ReNeuron's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of factors could cause ReNeuron's actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.